Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Crowther

Showing results (261-270 of 282) with videos related to

Pageof 29
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|June 17, 2016
Engineering of Isogenic Cells Deficient for MR1 with a CRISPR/Cas9 Lentiviral System: Tools To Study Microbial Antigen Processing and Presentation to Human MR1-Restricted T CellsBruno Laugel, Angharad Lloyd, Erin W Meermeier, et al.
Physiological Genomics|February 13, 2001
Identification and characterization of a novel human vanilloid receptor-like protein, VRL-2N S Delany, M Hurle, P Facer, et al.
British Medical Journal|December 4, 1976
Intensive investigation in management of Hodgkin's diseaseS B Sutcliffe, P F Wrigley, J F Smyth, et al.
British Journal of Cancer|November 1, 1973
Immunotherapy for acute myelogenous leukaemiaR L Powles, D Crowther, C J Bateman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma GroupA Le Cesne, I Judson, D Crowther, et al.
British Medical Journal|January 28, 1978
Combination chemotherapy for acute lymphoblastic leukaemia in adultsT A Lister, J M Whitehouse, M E Beard, et al.
Lancet (London, England)|April 16, 1983
Controlled trial of adjuvant chemotherapy with melphalan for breast cancerR D Rubens, J L Hayward, R K Knight, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study GroupM Loeffler, O Brosteanu, D Hasenclever, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancerA Weaver, J Chang, E Wrigley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's LymphomaJ Lundin, A Osterborg, G Brittinger, et al.
Pageof 29

Showing results (261-270 of 282) with videos related to

Sort By:
Pageof 29
Journal of Immunology (Baltimore, Md. : 1950)|June 17, 2016
Engineering of Isogenic Cells Deficient for MR1 with a CRISPR/Cas9 Lentiviral System: Tools To Study Microbial Antigen Processing and Presentation to Human MR1-Restricted T CellsBruno Laugel, Angharad Lloyd, Erin W Meermeier, et al.
Physiological Genomics|February 13, 2001
Identification and characterization of a novel human vanilloid receptor-like protein, VRL-2N S Delany, M Hurle, P Facer, et al.
British Medical Journal|December 4, 1976
Intensive investigation in management of Hodgkin's diseaseS B Sutcliffe, P F Wrigley, J F Smyth, et al.
British Journal of Cancer|November 1, 1973
Immunotherapy for acute myelogenous leukaemiaR L Powles, D Crowther, C J Bateman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma GroupA Le Cesne, I Judson, D Crowther, et al.
British Medical Journal|January 28, 1978
Combination chemotherapy for acute lymphoblastic leukaemia in adultsT A Lister, J M Whitehouse, M E Beard, et al.
Lancet (London, England)|April 16, 1983
Controlled trial of adjuvant chemotherapy with melphalan for breast cancerR D Rubens, J L Hayward, R K Knight, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study GroupM Loeffler, O Brosteanu, D Hasenclever, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancerA Weaver, J Chang, E Wrigley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's LymphomaJ Lundin, A Osterborg, G Brittinger, et al.
Pageof 29